Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

Georg Lenz

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

SOHO Highlights: State of the Art and Next Questions

G. Nowakowski

State of the Art and Next Questions: B-Cell Lymphoma

SOHO Highlights: State of the Art and Next Questions

L. Nastoupil

Frontline DLBCL Treatment Approaches

MyCancerHaven

R. Vij, H. Cherng

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Bispecifics for LBCL: Guidance for Management of Toxicities in the C…

UChicago Medicine

J. Crombie

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks